CAS: 334792-52-8; Methyl 3-Bromo-5-Fluorobenzoate

上下游产品

3-bromo-5-fluorobenzoic acid sodium hydrogencarbonate 3-bromo-5-fluorobenzonitrile 1,3-dibromo-5-fluorobenzenemethyl 3-cyano-5-fluorobenzoate 3-fluoro-5-pyridin-3-yl-benzoic acid methyl 3-fluoro-5-(2-trimethylsilylethynyl)benzoate methyl 3-cyano-5-fluoro-4-iodobenzoate

3-溴-5-氟苯腈置于氯化亚砜,水,三乙胺,Sodium Hydroxide体系中,化学反应 6.08H,反应生成3-溴-5-氟苯甲酸甲酯
参考文献:Discovery And Characterization Of Azd9272 And Azd6538-two Novel Mglur5 Negative Allosteric Modulators Selected For Clinical Development
标题:Discovery And Characterization Of Azd9272 And Azd6538-two Novel Mglur5 Negative Allosteric Modulators Selected For Clinical Development
摘要:Azd9272 And Azd6538 Are Two Novel Mglur5 Negative Allosteric Modulators Selected For Further Clinical Development. An Initial High-Throughput Screening Revealed Leads With Promising Profiles,Which Were Further Optimized By Minor,Yet Indispensable,Structural Modifications To Bring Forth These Drug Candidates. Advantageously,Both Compounds May Be Synthesized In As Little As One Step. Both Are Highly Potent And Selective For The Human As Well As The Rat Mglur5 Where They Interact At The Same Binding Site Than Mpep. They Are Orally Available,Allow For Long Interval Administration Due To A High Metabolic Stability And Long Half-Lives In Rats And Permeate The Blood Brain Barrier To A High Extent. Azd9272 Has Progressed Into Phase I Clinical Studies. (C) 2012 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Bmcl.2012.08.100